Jinan Hongyuan Chemical Co.,Ltd
86-176-86865661
On February 24, China biopharmaceutical announced the mid-term analysis of the phase III clinical trial of anti-PD-1 monoclonal antibody drug "panapril" (trade name: anico; R & D Code: ak105) jointly developed by the group and kangfang Biotechnology (Kaiman) Co., Ltd. in combination with paclitaxel and carboplatin for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer, reaching the main research end point.
The mid-term analysis results of this clinical study were reviewed by the independent data monitoring committee (IDMC). It showed that compared with placebo combined with paclitaxel and carboplatin, the combination of paclitaxel and carboplatin can significantly reduce the risk of disease progression or death. The main end point of this clinical study reached the pre-set optimal cut-off value. The safety characteristics were consistent with the previously reported results of paclitaxel and carboplatin The security of the system. The group and kangfang Biotechnology (Kaiman) Co., Ltd. plan to communicate with the drug audit center of the State Drug Administration of China on the application for the first-line treatment of squamous non-small cell lung cancer with panaprizumab combined with paclitaxel and carboplatin.
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.